Association between glucocorticoid-induced osteoporosis and myasthenia gravis: A cross-sectional study

Shingo Konno, Shigeaki Suzuki, Masayuki Masuda, Yuriko Nagane, Emiko Tsuda, Hiroyuki Murai, Tomihiro Imai, Toshiki Fujioka, Norihiro Suzuki, Kimiaki Utsugisawa

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Purpose: To investigate the association between glucocorticoid-induced osteoporosis and myasthenia gravis (MG) using a cross-sectional survey in Japan. Methods: We studied 363 patients with MG (female 68%; mean age, 57 ± 16 years) who were followed at six Japanese centers between April and July 2012. We evaluated the clinical information of MG and fractures, bone markers, and radiological assessment. Quality of life was measured using an MG-specific battery, MG-QOL15. Results: Glucocorticoids were administered in 283 (78%) of 363 MG patients. Eighteen (6%) of 283 MG patients treated with prednisolone had a history of osteoporotic fractures. The duration of glucocorticoid therapy, but not the dose of prednisolone, was associated with the osteoporotic fractures in MG patients. Bone mineral density was significantly decreased in the MG patients with fractures. The multivariate analyses showed that the total quantitative MG score was the only independent factor associated with osteoporotic fractures (OR = 1.30, 95% CI 1.02-1.67, p = 0.03). MG patients who had experienced fractures reported more severe difficulties in activities of daily living. Conclusion: Glucocorticoid-induced osteoporosis aggravates quality of life in patients with MG.

Original languageEnglish
Article numbere0126579
JournalPLoS One
Volume10
Issue number5
DOIs
Publication statusPublished - 2015 May 12

Fingerprint

Myasthenia Gravis
osteoporosis
glucocorticoids
cross-sectional studies
Glucocorticoids
Osteoporosis
Cross-Sectional Studies
prednisolone
Prednisolone
Osteoporotic Fractures
quality of life
Bone
bone fractures
bone density
Minerals
Quality of Life
Japan
Bone Fractures
therapeutics
Activities of Daily Living

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Association between glucocorticoid-induced osteoporosis and myasthenia gravis : A cross-sectional study. / Konno, Shingo; Suzuki, Shigeaki; Masuda, Masayuki; Nagane, Yuriko; Tsuda, Emiko; Murai, Hiroyuki; Imai, Tomihiro; Fujioka, Toshiki; Suzuki, Norihiro; Utsugisawa, Kimiaki.

In: PLoS One, Vol. 10, No. 5, e0126579, 12.05.2015.

Research output: Contribution to journalArticle

Konno, S, Suzuki, S, Masuda, M, Nagane, Y, Tsuda, E, Murai, H, Imai, T, Fujioka, T, Suzuki, N & Utsugisawa, K 2015, 'Association between glucocorticoid-induced osteoporosis and myasthenia gravis: A cross-sectional study', PLoS One, vol. 10, no. 5, e0126579. https://doi.org/10.1371/journal.pone.0126579
Konno, Shingo ; Suzuki, Shigeaki ; Masuda, Masayuki ; Nagane, Yuriko ; Tsuda, Emiko ; Murai, Hiroyuki ; Imai, Tomihiro ; Fujioka, Toshiki ; Suzuki, Norihiro ; Utsugisawa, Kimiaki. / Association between glucocorticoid-induced osteoporosis and myasthenia gravis : A cross-sectional study. In: PLoS One. 2015 ; Vol. 10, No. 5.
@article{a0a4447b39b04eaab257d8e07dd42256,
title = "Association between glucocorticoid-induced osteoporosis and myasthenia gravis: A cross-sectional study",
abstract = "Purpose: To investigate the association between glucocorticoid-induced osteoporosis and myasthenia gravis (MG) using a cross-sectional survey in Japan. Methods: We studied 363 patients with MG (female 68{\%}; mean age, 57 ± 16 years) who were followed at six Japanese centers between April and July 2012. We evaluated the clinical information of MG and fractures, bone markers, and radiological assessment. Quality of life was measured using an MG-specific battery, MG-QOL15. Results: Glucocorticoids were administered in 283 (78{\%}) of 363 MG patients. Eighteen (6{\%}) of 283 MG patients treated with prednisolone had a history of osteoporotic fractures. The duration of glucocorticoid therapy, but not the dose of prednisolone, was associated with the osteoporotic fractures in MG patients. Bone mineral density was significantly decreased in the MG patients with fractures. The multivariate analyses showed that the total quantitative MG score was the only independent factor associated with osteoporotic fractures (OR = 1.30, 95{\%} CI 1.02-1.67, p = 0.03). MG patients who had experienced fractures reported more severe difficulties in activities of daily living. Conclusion: Glucocorticoid-induced osteoporosis aggravates quality of life in patients with MG.",
author = "Shingo Konno and Shigeaki Suzuki and Masayuki Masuda and Yuriko Nagane and Emiko Tsuda and Hiroyuki Murai and Tomihiro Imai and Toshiki Fujioka and Norihiro Suzuki and Kimiaki Utsugisawa",
year = "2015",
month = "5",
day = "12",
doi = "10.1371/journal.pone.0126579",
language = "English",
volume = "10",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "5",

}

TY - JOUR

T1 - Association between glucocorticoid-induced osteoporosis and myasthenia gravis

T2 - A cross-sectional study

AU - Konno, Shingo

AU - Suzuki, Shigeaki

AU - Masuda, Masayuki

AU - Nagane, Yuriko

AU - Tsuda, Emiko

AU - Murai, Hiroyuki

AU - Imai, Tomihiro

AU - Fujioka, Toshiki

AU - Suzuki, Norihiro

AU - Utsugisawa, Kimiaki

PY - 2015/5/12

Y1 - 2015/5/12

N2 - Purpose: To investigate the association between glucocorticoid-induced osteoporosis and myasthenia gravis (MG) using a cross-sectional survey in Japan. Methods: We studied 363 patients with MG (female 68%; mean age, 57 ± 16 years) who were followed at six Japanese centers between April and July 2012. We evaluated the clinical information of MG and fractures, bone markers, and radiological assessment. Quality of life was measured using an MG-specific battery, MG-QOL15. Results: Glucocorticoids were administered in 283 (78%) of 363 MG patients. Eighteen (6%) of 283 MG patients treated with prednisolone had a history of osteoporotic fractures. The duration of glucocorticoid therapy, but not the dose of prednisolone, was associated with the osteoporotic fractures in MG patients. Bone mineral density was significantly decreased in the MG patients with fractures. The multivariate analyses showed that the total quantitative MG score was the only independent factor associated with osteoporotic fractures (OR = 1.30, 95% CI 1.02-1.67, p = 0.03). MG patients who had experienced fractures reported more severe difficulties in activities of daily living. Conclusion: Glucocorticoid-induced osteoporosis aggravates quality of life in patients with MG.

AB - Purpose: To investigate the association between glucocorticoid-induced osteoporosis and myasthenia gravis (MG) using a cross-sectional survey in Japan. Methods: We studied 363 patients with MG (female 68%; mean age, 57 ± 16 years) who were followed at six Japanese centers between April and July 2012. We evaluated the clinical information of MG and fractures, bone markers, and radiological assessment. Quality of life was measured using an MG-specific battery, MG-QOL15. Results: Glucocorticoids were administered in 283 (78%) of 363 MG patients. Eighteen (6%) of 283 MG patients treated with prednisolone had a history of osteoporotic fractures. The duration of glucocorticoid therapy, but not the dose of prednisolone, was associated with the osteoporotic fractures in MG patients. Bone mineral density was significantly decreased in the MG patients with fractures. The multivariate analyses showed that the total quantitative MG score was the only independent factor associated with osteoporotic fractures (OR = 1.30, 95% CI 1.02-1.67, p = 0.03). MG patients who had experienced fractures reported more severe difficulties in activities of daily living. Conclusion: Glucocorticoid-induced osteoporosis aggravates quality of life in patients with MG.

UR - http://www.scopus.com/inward/record.url?scp=84930674548&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930674548&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0126579

DO - 10.1371/journal.pone.0126579

M3 - Article

C2 - 25965387

AN - SCOPUS:84930674548

VL - 10

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 5

M1 - e0126579

ER -